back

EU Funding

Polpharma seeks EU funding to conduct R&D projects

Since the accession of Poland to the European Union in 2004, Polpharma has been applying for financial support to implement innovative projects under different funding programmes, both national and European. Until the end of 2009, Polpharma was awarded co-funding of a total of PLN 10 million to conduct 11 projects.

For information on projects under way, contact the Research & Development Department of Fine Chemicals Business Unit, tel. (58) 563 21 43, or the Research & Development Department of Pharma Business Unit, tel. (58) 563 88 91.

“Improvement of the Competitiveness of Enterprises” Sectoral Operational Programme

Within the framework of the 2004-2006 “Improvement of the Competitiveness of Enterprises” Polish Sectoral Operational Programmes (SPO-WKP), two projects developed by Polpharma’s Research & Development Department were awarded co-funding in the amount exceeding PLN 4.7 million.

The co-funding accounted for 35% of the eligible costs incurred.

The projects were aimed to develop formulas for therapeutic products used in the treatment of schizophrenia and to implement them into manufacture. The application for co-funding was filed under sub-measure 1.4.1 of the SPO-WKP: “Special targeted projects including applied research and development studies limited to industrial and pre-competitive research conducted by enterprises or groups of enterprises independently or in collaboration with R&D organisations”.

Links to websites with information on the “Improvement of the Competitiveness of Enterprises” Sectoral Operational Programme (SPO-WKP):

The Structural Funds website
Ministry of Science and Higher Education sites
Ministry of Economy sites

“Innovative Economy” Operational Programme

Polpharma was awarded EU grants to implement 5 projects under the 2007-2013 “Innovative Economy” Operational Programme (POIG), measure 1.4-4.1: “Support for special targeted projects and the implementation of results of R&D studies.”

The applications were submitted to the Polish Agency for Enterprise Development (PARP) in response to the call for applications under measure 1.4-4.1 of the POIG programme:

  • round 1, 2009 for enterprises other than SME; total aid: PLN 5,336,247;
    The co-funding was awarded to 2 R&D projects developed by Pharma Business Unit:
    1. Development of an innovative formula and implementation into manufacture of a product for the treatment of fungal diseases;
    2. Development of an innovative formula and implementation into manufacture of a product for the treatment of depressive syndromes;
  • and 3 R&D projects developed by Fine Chemicals Business Unit:
    1. Development of an innovative technology for pharmaceutical manufacturing of the active ingredient Aliskiren
    2. Technologies for pharmaceutical manufacturing of the active ingredient Sitagliptin
    3. Development and implementation of an innovative technology for pharmaceutical manufacturing of the following active ingredients: Montelukast sodium, Pentoxifylline and Orlistat using micro-reactor flow processes and affinity chromatography
  • round 2, 2009 for enterprises other than SME; total aid: PLN 1,498,775; The co-funding was awarded to an R&D project developed by Pharma Business Unit:
    1. Development of an innovative formula and implementation into manufacture of a product preventing chemotherapy-induced nausea and vomiting